April 27, 2020 / 8:12 PM / a month ago

BRIEF-Syndax - Preclinical Profile And Initial Phase 1 Data Demonstrating Clinical Activity Of Menin Inhibitor Sndx-5613 In Adults With Relapsed/Refractory Acute Leukemias

April 27 (Reuters) - Syndax Pharmaceuticals Inc:

* SYNDAX PHARMACEUTICALS ANNOUNCES PRECLINICAL PROFILE AND INITIAL PHASE 1 DATA DEMONSTRATING CLINICAL ACTIVITY OF MENIN INHIBITOR SNDX-5613 IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS

* SYNDAX - PRELIM RESULTS REPRESENT 1ST CLINICAL EVIDENCE THAT INHIBITION OF MENIN-MLL1 INTERACTION CAN INDUCE RESPONSE IN MLL-R ACUTE LEUKEMIAS PATIENTS

* SYNDAX - U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO SNDX-5613 FOR TREATMENT OF ADULT AND PEDIATRIC ACUTE MYELOID LEUKEMIA

* SYNDAX - EXPECTS TO PRESENT ADDITIONAL RESULTS FROM AUGMENT-101 AT A MEDICAL CONFERENCE IN Q4 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below